Thematic Exposure -- 7/10
Theme: End-Stage Renal Disease (ESRD) / dialysis — a structurally growing, chronic, recurring-treatment
healthcare niche. FMS is the world's #1 integrated dialysis franchise: it both operates dialysis clinics
(Care Delivery) and manufactures the machines, dialyzers, and consumables those clinics consume (Care
Enablement), plus a smaller value-based-care payer arm. The rare case where a company is dominant on both
sides of its own value chain. Clears the oligopoly hard gate decisively — but held to 7 (not 9-10) by
a ~37-38% (not >50%) primary segment, a mid-single-digit (not >10%) theme, and price-taker exposure
to Medicare-administered rates.
Weight: 35%
Segment mix (latest quarter, 2026Q1, EUR m)
| Segment | Revenue | % Rev | Market Share |
|---|---|---|---|
| Care Delivery | €3,293.6m | ~64% | ~37-38% of U.S. outpatient dialysis (co-leader of an ~80% duopoly with DaVita) |
| Care Enablement | €1,299.0m | ~25% | Global #1 in HD machines & dialyzers; FMS + Baxter/Vantive >50% of the equipment market |
| Value-Based Care | €490.4m | ~9% | Small renal-VBC payer/risk arm; not a market leader |
| Total | €4,612.0m | 100% | Total dialysis market ~$113B (2024) → ~$170-192B by 2030-2034 |
FY2025 full-year mix (Daloopa) corroborates the structure: total revenue €19,627.6m,
Care Delivery €13,736.3m (~70%),
Care Enablement €5,476.2m (~28%). FY mix shows
Care Delivery higher because VBC is consolidated into Care Delivery in the annual roll-up; the quarterly view breaks VBC out.
Structurally growing theme -- strong
Secular Tailwind -- Chronic, Recurring, Non-Discretionary
The global dialysis market grows ~5-8% CAGR toward ~$170-192B by the early 2030s on rising CKD
prevalence. Dialysis is chronic and non-discretionary — a patient is tethered to a clinic 3x/week
for life. The HVHDF / 5008X rollout (~100 clinics, >100k treatments by early April 2026) is an
internal upgrade lever that deepens device lock-in and, management argues, reduces mortality.
Duopoly + device #1 -- clears the oligopoly gate
Oligopoly Gate: PASS
Care Delivery is effectively a two-firm market — FMS (~37-38%) and DaVita (~37%); the next tier
(U.S. Renal Care, DCI, Satellite) is each well below 15%. Care Enablement has one-to-two players
above 15% globally — FMS (#1) and Baxter/Vantive, together >half the equipment market; B. Braun,
Nipro, Asahi/Toray are sub-scale in machines. Both core segments are concentrated, not fragmented —
one of ≤3 players controlling >70% of each, with >30% share in the primary segment.
Price-taker exposure -- the structural ceiling
Mixed Pricing Power -- Why This Is a 7, Not a 9-10
In the U.S., the bulk of Care Delivery revenue is Medicare/Medicaid at administered (government-set)
rates — FMS is a price-taker on its largest revenue pool, with profit driven by
commercial-payer mix and cost control rather than pricing power. It does set prices in Care Enablement
(proprietary premium devices / HDF) and commercial negotiations, but the government-rate exposure
(and TDAPA / ACA-subsidy sensitivity) means it is not a clean price-setter. This is the key reason the
score is a 7.
Oligopoly gate -- the three questions
| Criterion | Result |
|---|---|
| Competitors with >15% share (Care Delivery) | Two (FMS ~37-38%, DaVita ~37%) — duopoly |
| Competitors with >15% share (devices) | One-to-two (FMS #1 + Baxter) >50% |
| Customer replace FMS within 12 months? | No — very high switching costs |
| Does FMS set or take prices? | Mixed — price-taker on Medicare |
| Gate result | PASS |
Durability, buyers, and what could replace it
- Durability: Regulatory moat (clinic CON/licensing, FDA-cleared devices), a vertically integrated cost advantage (it makes what its own clinics use), patient stickiness, and a 50+ year installed base. The HVHDF/5008X rollout deepens device lock-in.
- Buyers: Care Delivery — Medicare/Medicaid (administered) plus commercial MCOs; patients are referred, not shopping. Care Enablement — FMS's own clinics plus third-party operators (incl. DaVita) and international/government health systems. VBC — risk-bearing payer relationships.
- What could replace it: slow-moving decade-scale theme risks only — (a) GLP-1s / CKD-progression drugs and transplant advances shrinking the ESRD funnel (management argues GLP-1s may extend ESRD survival near-term); (b) home/peritoneal dialysis shifting volume away from in-center economics (FMS plays in home too, partially hedged); (c) U.S. reimbursement/subsidy cuts. None is a 12-month replacement.
Assessment
7/10 — FMS clears the oligopoly hard gate
decisively: it co-leads an ~80% two-firm U.S. clinic duopoly (~37-38% share) and is the global #1 in
dialysis equipment with Baxter the only peer above 15% — comfortably >30% share in its primary segment
and one of ≤3 players controlling >70% in both core segments. The theme is structurally growing (~5-8%
CAGR toward ~$170-192B), switching costs are high, and vertical integration is a real cost moat. What holds
this at a 7 rather than 9-10 is that the rubric's top tier requires >50% share AND >10% theme growth
AND clean oligopoly pricing: FMS's largest segment is ~37-38% (not >50%), the theme grows mid-single
digits (not >10%), and the company is a price-taker on the majority of its revenue (Medicare-administered
rates), with TDAPA/ACA sensitivity and soft U.S. same-market treatment volume capping the upside.
Data sourced from Daloopa (segment revenue) and web research (market share / TAM): GMInsights U.S. dialysis, Fortune Business Insights, NextMSC dialysis share, Matthews dialysis 2025.